Establishing best practices in

Manufacturing and Personalized
Patient care is our goal

Our manufacturing facility
is equipped to achieve a

rapid and consistent
manufacturing time
of approximately 2 weeks

  • Our facility is positioned to produce 4,000 to 5,000 patient therapies a year
  • Central manufacturing of CAR T cells has been optimized with the goal of rapid, robust, and consistent manufacturing in a multicenter setting3
  • Chain of identity is maintained through a single point of control
  • Chain of custody of the product is designed to be secure at all times

References: 1. Sharpe M, Mount N. Dis Model Mech.
2015;8(4):337-350. 2. Wang X, Riviere I. Mol Ther Oncolytics. 2016;3:16015.
3. Data on File. Kite Pharma 2017.